Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?

[1]  Vinay Shah,et al.  Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation , 2022, JAMA network open.

[2]  B. Lewis,et al.  Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. , 2022, European heart journal. Cardiovascular pharmacotherapy.

[3]  A. Genaidy,et al.  Prevalence/incidence of atrial fibrillation based on integrated medical/pharmacy claims, and association with co‐morbidity profiles/multi‐morbidity in a large US adult cohort , 2021, International journal of clinical practice.

[4]  G. Lip,et al.  Effectiveness and Safety of Oral Anticoagulants Among Non-Valvular Atrial FibrillationPatients with Polypharmacy. , 2020, European heart journal. Cardiovascular pharmacotherapy.

[5]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[6]  E. Benjamin,et al.  Epidemiology of Atrial Fibrillation in the 21st Century , 2020, Circulation research.

[7]  D. Malone,et al.  Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis , 2020, Thrombosis and Haemostasis.

[8]  L. Chen,et al.  Polypharmacy, Adverse Outcomes, and Treatment Effectiveness in Patients ≥75 With Atrial Fibrillation , 2020, Journal of the American Heart Association.

[9]  Christopher X. Wong,et al.  Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis , 2020, Open Heart.

[10]  M. A. Esteve-Pastor,et al.  Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation , 2019, BMJ Open.

[11]  H. Munro,et al.  Polypill for Cardiovascular Disease Prevention in an Underserved Population. , 2019, The New England journal of medicine.

[12]  P. Wild,et al.  Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists , 2018, Journal of the American Geriatrics Society.

[13]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[14]  G. Lip,et al.  Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality , 2018, International journal of clinical practice.

[15]  M. Martín-Pérez,et al.  Population Impact of Drug Interactions with Warfarin: A Real-World Data Approach , 2018, Thrombosis and Haemostasis.

[16]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[17]  G. Lip.  The ABC pathway: an integrated approach to improve AF management , 2017, Nature Reviews Cardiology.

[18]  B. Bajorek,et al.  Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation , 2016, Pharmacy practice.

[19]  Michael A. Chen.  Multimorbidity in Older Adults with Atrial Fibrillation. , 2016, Clinics in geriatric medicine.

[20]  G. Lip,et al.  Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial , 2016, Clinical Research in Cardiology.

[21]  G. Breithardt,et al.  Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation , 2016, Circulation.

[22]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[23]  Danijela Gnjidic,et al.  Reducing inappropriate polypharmacy: the process of deprescribing. , 2015, JAMA internal medicine.

[24]  G. Davı̀,et al.  Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study , 2014, Internal and Emergency Medicine.

[25]  Simon Stewart,et al.  Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. , 2013, International journal of cardiology.

[26]  H. Leufkens,et al.  The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non‐valvular atrial fibrillation , 2013, Journal of thrombosis and haemostasis : JTH.

[27]  Salvatore Corrao,et al.  Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study , 2011, European Journal of Clinical Pharmacology.

[28]  E. Hylek,et al.  New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs , 2010, Thrombosis and Haemostasis.

[29]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[30]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.